3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow

Eli Lilly is a leader in the GLP-1 weight-loss drug market with exceptional sales growth for Mounjaro and Zepbound. Despite a high P/E ratio of 40x, the company is growing into its valuation. Eli Lilly continues to innovate with GLP-1 pill versions and is strategically acquiring companies in infectious disease to build a diversified portfolio beyond GLP-1 drugs as patent protection eventually expires.